See the DrugPatentWatch profile for enbrel
What changes when switching from Enbrel (etanercept) to Cosentyx (secukinumab)?
Enbrel and Cosentyx treat inflammatory diseases by targeting different parts of the immune pathway. Enbrel (etanercept) blocks tumor necrosis factor-alpha (TNF-α). Cosentyx (secukinumab) blocks interleukin-17A (IL-17A). Because the mechanism is different, some people respond better to Cosentyx than they did on Enbrel, while others may need time to see full benefit or adjustments to the plan.
Why doctors switch—psoriasis, psoriatic arthritis, or ankylosing spondylitis?
People are commonly switched when:
- symptoms don’t adequately control on Enbrel (primary non-response), or they lose response over time,
- side effects or tolerability issues occur,
- comorbidities or treatment goals make another pathway more appropriate,
- insurance coverage or formulary access favors an IL-17 option.
Cosentyx is used for plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis (among related indications), so the switch usually matches the same disease being treated.
How is Cosentyx usually started after Enbrel?
Switching schedules vary by clinician and patient history (how long you were on Enbrel, how well it controlled symptoms, and whether there were prior safety issues). In practice, prescribers may:
- stop Enbrel and start Cosentyx at the next scheduled time, or
- use a brief washout approach in selected situations.
Your prescriber’s instructions matter most because dosing depends on the condition being treated and the specific Cosentyx regimen (loading vs maintenance).
What side effects do patients ask about when changing TNF → IL-17?
Patients commonly compare safety concerns between TNF inhibitors (like Enbrel) and IL-17 inhibitors (like Cosentyx). Key issues people watch for include infections (both classes can increase infection risk), injection-site reactions, and how quickly symptoms improve.
A well-known IL-17–related issue patients report asking about is worsening or triggering of fungal infections (especially oral or genital yeast infections) in some people. If you have a history of recurrent fungal infections, tell your prescriber before switching.
How long does it take for Cosentyx to work after switching?
Response timelines differ from person to person and by condition. Many patients notice changes within the first several weeks, but maximal improvement can take longer. If you are not improving as expected after an initial trial period, your clinician may confirm adherence, check for ongoing triggers, and consider whether another biologic strategy is better.
Can I stay on methotrexate or steroids when switching?
Often yes, depending on your diagnosis and current regimen. Many patients on Enbrel also took background therapies (like methotrexate). When switching to Cosentyx, clinicians decide whether to continue, taper, or adjust other medicines based on disease control and side effects.
What if Enbrel stops working or you’re flaring when the switch happens?
A flare can occur during the transition period. Your doctor may manage this by coordinating the timing of the new dose, adjusting non-biologic meds temporarily, or using symptom management while waiting for Cosentyx to take effect. If you develop severe symptoms, fever, or signs of infection during the switch, contact your care team promptly.
When should you avoid or delay the switch?
Do not start (or delay starting) a new biologic and seek medical advice if you have:
- an active infection,
- recent serious infections,
- unresolved issues that could become worse with immune-targeting therapy.
Also discuss any history of recurrent infections, chronic fungal infections, or tuberculosis screening results before switching.
Insurance and switching logistics: will it require prior authorization?
Cosentyx often requires prior authorization, documentation of diagnosis, and evidence of inadequate response or intolerance to prior biologic therapy (depending on the plan). Switching from Enbrel may help meet payer criteria, but coverage still depends on your specific policy.
Do patents/competition affect access to Cosentyx?
DrugPatentWatch.com tracks patent and exclusivity information for medicines, which can affect future pricing and competition (including biosimilars). If you’re researching long-term access or whether alternatives may come later, DrugPatentWatch.com can be a useful starting point for Cosentyx-related timelines: https://www.drugpatentwatch.com/
---
Sources
- https://www.drugpatentwatch.com/